Nasdaq rxrx.

Nov 21, 2023 · Cathie Wood can't get enough of Recursion Pharmaceuticals (RXRX-3.13%) stock. Through her Ark Innovation ETF, the maverick growth stock portfolio manager bought shares of the biotech three times ...

Nasdaq rxrx. Things To Know About Nasdaq rxrx.

Find the latest analyst research for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. ... Based on analysts offering 12 month price targets for RXRX in the last 3 months. That's what's happening with Recursion Pharmaceuticals ( RXRX -4.40%), an innovative biotech. The company's shares are currently changing hands for $7.07 apiece, but the consensus one-year target ...Jan 4, 2024 · Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ... The idea of Recursion Pharmaceuticals (RXRX-4.65%) is to throw petabytes of data on biological targets, chemical interactions, and bioactive molecules at a machine learning platform to identify ...Recursion Pharmaceuticals (NASDAQ: RXRX) is a clinical stage company that mixes healthcare with technology and artificial intelligence (AI). Its drug discovery platform, Recursion OS, is the key ...

Get the latest updates on Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) after hours trades, after hours share volumes, and more. Make informed investments with Nasdaq.

Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...

Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ...RECURSION PHARMACEUTICALS INC ( RXRX) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 43% based on the firm’s underlying fundamentals and the ...Nov 15, 2023 · AI-driven drug discovery firm Recursion Pharmaceuticals (NASDAQ:RXRX) added ~17% on Wednesday after ARK Innovation ETF (NYSEARCA:ARKK), managed by famous stock picker Cathie Wood, bought ~3.8M of ... Get the latest Recursion Pharmaceuticals Inc (RXRX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment...

Institutional investors have sold a total of 19,621,281 shares in the last 24 months. This volume of shares sold represents approximately $160.50M in transactions. Related Companies: ImmunityBio Institutional Ownership. Neumora Therapeutics Institutional Ownership. This page (NASDAQ:RXRX) was last updated on 1/15/2024 …

Market Activity. Funds + ETFs. News + Insights. P/E & PEG Ratios. Nasdaq provides the ownership stake information in a company, including the number of shares held by those institutions in a firm ...

July 13, 2023 — 11:01 am EDT. Written by Zacks Equity Research for Zacks ->. Recursion Pharmaceuticals RXRX announced a significant investment worth $50 million from NVIDIA Corporation NVDA, a ...Find the latest Financials data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.NASDAQ:RXRX opened at $9.78 on Friday. Recursion Pharmaceuticals has a 1 year low of $4.54 and a 1 year high of $16.75. The stock has a market cap of $2.12 billion, a price-to-earnings ratio of -6.70 and a beta of 0.63.The firm has a market cap of $2.09 billion, a PE ratio of -6.60 and a beta of 0.63. Recursion Pharmaceuticals ( NASDAQ:RXRX – Get Free Report) last announced its earnings results on Thursday ...Fintel reports that on July 12, 2023, Needham reiterated coverage of Recursion Pharmaceuticals Inc - (NASDAQ:RXRX) with a Buy recommendation.. Analyst Price Forecast Suggests 117.07% Upside. As of ...Recursion Pharmaceuticals Inc Insider Sells Shares. Shafique Virani, Chief Business Officer of Recursion Pharmaceuticals Inc (NASDAQ:RXRX), sold 18,000 shares of the company on January 16, 2024, according to a recent SEC Filing. Insider Monkey.Stocks RXRX Recursion Pharmaceuticals Stock (NASDAQ:RXRX): Small Company, Big Future December 14, 2023 — 02:31 pm EST Written by Sushree Mohanty …

Shares of Recursion Pharmaceuticals (RXRX-2.63%) were skyrocketing 82% higher this week as of the market close on Thursday, according to data provided by S&P Global Market Intelligence.Platinum Investment Management Ltd. lessened its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 13.9% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission.The fund owned 2,335,132 shares of the company's stock after selling …Market Activity. Funds + ETFs. News + Insights. P/E & PEG Ratios. Nasdaq provides the ownership stake information in a company, including the number of shares held by those institutions in a firm ... Aug 11, 2023 · NASDAQ: RXRX Recursion Pharmaceuticals. Market Cap. $2B. Today's Change (-2.63%) -$0.26 ... When it comes to complex biotech stocks like Recursion Pharmaceuticals (RXRX-2.63%), skilled investors ... Feb 17, 2023 · Recursion Pharmaceuticals (NASDAQ:RXRX) - the subject of this analysis - IPOd in April 2021, issuing 27.88m shares at a price of $18 per share, and raising >$500m - making it the sixth largest ... Nov 21, 2023 · Cathie Wood can't get enough of Recursion Pharmaceuticals (RXRX-3.13%) stock. Through her Ark Innovation ETF, the maverick growth stock portfolio manager bought shares of the biotech three times ... On October 25, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) announced that it has entered into a stock purchase agreement for the sale of approximately 15.3 million units of its common stock in a ...

With a relentless focus on transforming the biotechnology landscape through its artificial intelligence (AI) and machine learning (ML) driven platform, Recursion Pharmaceuticals (NASDAQ:RXRX ...December 29, 2023. Shares of Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX - Get Free Report) dropped 1.9% on Friday following insider selling activity. The stock traded as low as $10.41 and last traded at $10.41. Approximately 154,367 shares changed hands during mid-day trading, a decline of 96% from the average daily volume of 3,473,452 …

Recursion Pharmaceuticals, Inc. (RXRX) High-Resolution Genome-Wide Mapping of Chromosome-Arm-Scale Truncations Induced by CRISPR-Cas9 Editing CRISPR-Cas9 editing is a scalable technology for mapping of biological pathways, but it has been reported to cause a variety of undesired large-scale structural changes to the genome. Institutional investors have sold a total of 19,621,281 shares in the last 24 months. This volume of shares sold represents approximately $160.50M in transactions. Related Companies: ImmunityBio Institutional Ownership. Neumora Therapeutics Institutional Ownership. This page (NASDAQ:RXRX) was last updated on 1/15/2024 …Jan 2, 2024 · But Recursion Pharmaceuticals (NASDAQ: RXRX) is accelerating drug discovery using artificial intelligence . This novel approach makes RXRX a top biotech stock to capture the broad longevity trend. 114% vs Avg 9.70 Day Range 10.68 4.54 52 Week Range 16.75 Partner Center Your Watchlists Customize MarketWatch Have Watchlists? Log in to see them here or sign …Jan 19, 2024 · Stock analysis for Recursion Pharmaceuticals Inc (RXRX:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. ... Nasdaq GS (USD) As of 12: ... Nasdaq Futures 17,538.50 +100.00(+0.57%) Russell 2000 Futures 1,961.90 +7.10(+0.36%) Crude Oil 73.13 -0.28(-0.38%) Gold 2,023.30 -6.00(-0.30%) Recursion Pharmaceuticals, Inc. (RXRX) NasdaqGS -... N/A Dividend Yield N/A Price Target $11.20 Stock Analysis Analyst Forecasts Chart Competitors Earnings Financials Headlines Insider Trades Ownership SEC Filings …

Find the latest analyst research for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. ... Based on analysts offering 12 month price targets for RXRX in the last 3 months.

Nov 22, 2023 · That's what's happening with Recursion Pharmaceuticals (NASDAQ: RXRX), an innovative biotech. The company's shares are currently changing hands for $7.07 apiece, but the consensus one-year target ...

Shares of NASDAQ:RXRX opened at $10.23 on Friday. Recursion Pharmaceuticals, Inc. has a 52 week low of $4.54 and a 52 week high of $16.75. The firm’s 50 day moving average is $9.27 and its two ...Dec 22, 2023 · The NASDAQ 100 After Hours Indicator is down -8.22 to 16,769.18. The total After hours volume is currently 64,637,594 shares traded.The following are the most active stocks for the after hours ... The firm has a market cap of $2.09 billion, a PE ratio of -6.60 and a beta of 0.63. Recursion Pharmaceuticals ( NASDAQ:RXRX – Get Free Report) last announced its earnings results on Thursday ...The idea of Recursion Pharmaceuticals (RXRX-4.65%) is to throw petabytes of data on biological targets, chemical interactions, and bioactive molecules at a machine learning platform to identify ...RECURSION PHARMACEUTICALS INC ( RXRX) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 43% based on the firm’s underlying fundamentals and the ...Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.Director Blake Borgeson of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) has sold 20,054 shares of the company on January 23, 2024, according to a recent SEC Filing ...1 day ago · The Nasdaq Composite rose like a phoenix from the ashes in 2023, but history suggests there's more growth to come. Generative AI kick-started the market last year, but it's still early innings for ... Jan 17, 2024 · Across the recent three months, 4 analysts have shared their insights on Recursion Pharmaceuticals (NASDAQ:RXRX), expressing a variety of opinions spanning from bullish to bearish. Jan 12, 2024 · imagedepotpro. Investment Overview. The last time I covered Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) for Seeking Alpha was back in May last year, when I gave the company's stock a "hold ... In the previous quarter, Recursion Pharmaceuticals (NASDAQ:RXRX) missed the analysts' consensus estimate of ($0.38) by $0.05 with a reported earnings per share …Shares of Recursion Pharmaceuticals ( RXRX -4.40%) sank 17.7% lower as of the market close on Wednesday. The decline came after the company provided its third-quarter update Wednesday morning ...

NASDAQ:RXRX opened at $9.78 on Friday. Recursion Pharmaceuticals has a 1 year low of $4.54 and a 1 year high of $16.75. The stock has a market cap of $2.12 billion, a price-to-earnings ratio of -6 ...(NASDAQ: RXRX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 9.91%. What is RXRX's Price Target? According to 5 Wall Street analyst s that have issued a 1 year RXRX price target, the average RXRX price target is $16.80 , with the highest RXRX stock price forecast at $33.00 and the lowest RXRX stock price …There are a couple of particularly risky stocks that AI investors have been gravitating toward this year that you're better off avoiding. Recursion Pharmaceuticals ( RXRX 8.83%) and C3.ai ( AI 6. ...Instagram:https://instagram. pre workoutscxpericd 10 code for cbc screeninglogmein rescue login Health Care Sector Update for 01/04/2024: SEM, XERS, RXRX, OMGA, NVO January 04, 2024 — 03:53 pm EST Written by MT Newswires for MTNewswires ->Nasdaq Insider Activity page provides trading information of corporate insiders (officers, directors and any beneficial owners of more than 10% of a class of the company’s equity securities). nremt skill sheets pdfsampercent27s club humble gas price The last time I mentioned Recursion Pharmaceuticals (NASDAQ:RXRX), it traded around $10.75 on Aug. 8. While the stock dipped to about $8.58 following that note, there’s still a lot to like here. dark web communities Stocks RXRX Recursion Pharmaceuticals Stock (NASDAQ:RXRX): Small Company, Big Future December 14, 2023 — 02:31 pm EST Written by Sushree Mohanty …Jan 8, 2024 · SAN FRANCISCO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today presented a ... Biotech firm Recursion (NASDAQ:RXRX) said on Wednesday that it had secured a $50M investment from Nvidia , which was implemented as a private investment in public equity. RXRX shares jump +72.7% ...